Cargando…
Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program
AIMS/HYPOTHESIS: The primary analysis of the Canagliflozin cardioVascular Assessment Study (CANVAS) Program showed canagliflozin to have a beneficial effect on cardiovascular and renal outcomes in people with type 2 diabetes at high cardiovascular risk, but also an unexpected increased risk of major...
Autores principales: | Matthews, David R., Li, Qiang, Perkovic, Vlado, Mahaffey, Kenneth W., de Zeeuw, Dick, Fulcher, Greg, Desai, Mehul, Hiatt, William R., Nehler, Mark, Fabbrini, Elisa, Kavalam, Mary, Lee, Mary, Neal, Bruce |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509073/ https://www.ncbi.nlm.nih.gov/pubmed/30868176 http://dx.doi.org/10.1007/s00125-019-4839-8 |
Ejemplares similares
-
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
por: Mahaffey, Kenneth W., et al.
Publicado: (2018) -
Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program
por: Zhou, Zien, et al.
Publicado: (2019) -
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
por: Rådholm, Karin, et al.
Publicado: (2018) -
Canagliflozin and Stroke in Type 2 Diabetes Mellitus: Results From the Randomized CANVAS Program Trials
por: Zhou, Zien, et al.
Publicado: (2019) -
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program
por: Neuen, Brendon L., et al.
Publicado: (2018)